NCT06038253Not yet recruiting
Relation Between NAFLD and BM DENSITY
Relation Between Non- Alcoholic Fatty Liver Disease and Bone Mineral Density in Egyptian Adults
Source: ClinicalTrials.gov · Last updated 15 Sept 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In general NAFLD is a common denominal for a broad spectrum of damage to the liver, which can be due to hepatocyte injury, inflammatory processes and fibrosis. This is normally seen on liver biopsy and can range from milder forms (steatosis) to the more severe forms (non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis and liver failure). In these patients, advanced fibrosis is the major predictor of morbidity and liver-related mortality, and an accurate diagnosis of NASH and NAFLD is mandatory . NAFLD is closely associated with metabolic disorders, including central obesity, dyslipidaemia, hypertension, hyperglycaemia and persistent abnormalities of liver function tests. NAFLD was shown to be connected with diseases that are usually not dependent on obesity, such as sarcopenia and osteoporosis Target of the study : 1. Clarify predictive value of fibroscan and u/s in diagnosis of NAFLD. 2. Estimate the metabolic effect of NAFLD on bone density 3. Estimate the correlation between obesity , NAFLD and BMD
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 8 Sept 2023
- Start date
- 1 Oct 2023
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Assiut University
- NCT number
- NCT06038253
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Oct 2023 to the primary completion date, 1 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1- Patients less than 18 y.o 2- Patients known alcohol abuser of ≥30 g/day in men or≥20 g/day in women. 3- Patients with chronic liver disease or HCC. 4- Subjects with suspected or proven any other liver disease other than NAFLD as (viral hepatitis, drug-induced liver injury, autoimmune liver disease, Wilson's disease or primary biliary cholangitis).
- 5- none of the subjects followed specific diets or therapeutic treatments that could influence BMD or liver function.
- 6- Patients with conditions known to affect bone metabolism, such as kidney, thyroid or parathyroid diseases, bone tumors 7- (iv) Postmenopausal females to avoid the increased risk of osteoporosis in those patients due to hormonal changes.
Who the study is looking for
- \- INCLUSION CRITERIA
- Patients above the age of 18 y.o and premenopausal females
- Patients showing any degree of fibrosis and steatosis .
- Patients suffers from obesity and its complications
- Patients with hyperlipidemia and DM
- NAFLD patients were diagnosed with an ultrasound examination or fibroscan or pathological examination to make a clear and definite diagnosis,
- all the obese participants according to body mass index (BMI)
- BMD was measured by dual energy X-ray absorptiometry.
Age in the registry: 18 years to 50 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.